Methylprednisolone Sodium Succinate for Injection 40mg. 10vials/Box

• Dosage Form: Powder Injection
• Dossier: Ready
• Usfda: Ready
• Transport Package: Carton
• Specification: 40mg
• Trademark: Sinolead
• Model NO.: Powder Injection
• Origin: China

Product Description

Basic Info.

 

Generic Name	Methylprednisolone Sodium Succinate For Injection 40mg
Strength	40mg
Packing	10vials/box
Origin	China

Component:
Methylprednisolone Sodium Succinate For Injection 40mg.

Character:
This product is white to white - like loose mass or powder.

Indications:

Unless used as an alternative treatment for certain endocrine disorders, glucocorticoids are only a symptomatic treatment.

1. Anti-inflammatory therapy: - Rheumatic diseases: as an adjunct for short-term use (to help patients through the acute or critical phase) for: post-traumatic osteoarthritis; Synovitis due to osteoarthritis; Rheumatoid arthritis, including juvenile rheumatoid arthritis (individual patients may require low-dose maintenance therapy); Acute or subacute bursitis; Superior malleolitis; Acute nonspecificity.

2. Immunosuppressive therapy: organ transplantation.

3. Treatment of hematologic diseases and tumors: - Hematologic diseases: acquired (autoimmune) hemolytic anemia; Adult spontaneous thrombocytopenic purpura (intravenous injection only allowed, intramuscular injection contraindicated); Adult secondary thrombocytopenia; Hypoerythroblast (erythrocyte anemia); Congenital hypoplastic anemia. - Cancer: palliative care for: adult leukaemia and lymphoma; Acute leukemia in children.

4. Therapeutic shock: Shock induced by adrenal cortical insufficiency or shock that does not respond to conventional treatment due to adrenal cortical insufficiency (hydrocortisone is commonly used; Methylprednisolone can be used if you do not wish to have halocorticoid activity). Hemorrhagic, traumatic, and surgical shock that did not respond to conventional treatment. Although there are no well-developed (double-blind controlled) clinical studies, data from animal studies suggest that Miloxone (r) may be effective in treating shock that does not respond to conventional therapy (e.g., rehydration). Also see "Septic Shock" in the "Precautions" section.

5. Others: - Nervous system: cerebral edema due to primary or metastatic tumors, and/or surgery and radiotherapy; Traumatic cerebral edema; Acute critical stage of multiple sclerosis; Treatment for acute spinal cord injury should begin within 8 hours after trauma. - In conjunction with appropriate antituberculous chemotherapy for tuberculous meningitis with subarachnoid obstruction or tending to obstruction. Trichinosis involving the nerves or heart muscle. - Prevent nausea and vomiting caused by cancer chemotherapy.

6. Endocrine disorders: primary or secondary adrenal cortical insufficiency; Acute adrenocortical insufficiency; (Hydrocortisone or cortisone is the preferred drug for these diseases. Synthetic glucocorticoids can be used in combination with corticosteroids if necessary.) In patients known to have or likely to have adrenal cortical insufficiency, medication is given in the event of severe trauma or disease. Congenital adrenal hyperplasia; Nonsuppurative thyroiditis; Hypercalcemia due to cancer.

 

Usage and dosage:

As an adjunct to life threatening conditions: The recommended dose is 15 to 30mg/kg BW for at least 30 minutes intravenously. Depending on clinical needs, this dose can be repeated in the hospital every 4-6 hours over a 48-hour period.

Precautions:

Systemic adverse reactions may be observed. Although rarely seen during short-term treatment, careful follow-up is warranted. This is part of the follow-up for steroid therapy and is not specific to any particular drug. Possible adverse effects of glucocorticoids (e.g., methylprednisolone) are: fluid and electrolyte disturbances: equivalent to cortisone and hydrocortisone, synthetic derivatives (e.g., methylprednisolone) have less salocorticoid effects.